Michael Guerrera
Overview
Explore the profile of Michael Guerrera including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
66
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Toner K, Srinivasalu H, Guerrera M, Shirron K, Bandarkar A, Diamond C, et al.
Pediatrics
. 2018 Oct;
142(5).
PMID: 30287592
A 17-year-old girl presented to her primary care physician with a history of unintentional weight loss and vague sensory symptoms, including tingling of her lower extremities. She had a nonrevealing...
2.
Croteau S, Callaghan M, Davis J, Dunn A, Guerrera M, Khan O, et al.
Res Pract Thromb Haemost
. 2018 Jul;
2(3):607-614.
PMID: 30046766
Background: Emergence of population pharmacokinetic models for prediction of individual pharmacokinetic (PK) profiles facilitates individualization of prescribed prophylactic therapy for patients with hemophilia A and B and may have a...
3.
Abla O, Weitzman S, Blay J, Patrick ONeill B, Abrey L, Neuwelt E, et al.
Clin Cancer Res
. 2011 Jan;
17(2):346-52.
PMID: 21224370
Purpose: To describe the demographic and clinical features and outcomes for children and adolescents with primary CNS lymphoma (PCNSL). Experimental Design: A retrospective series of children and adolescents with PCNSL...
4.
Kumar S, Pittaluga S, Raffeld M, Guerrera M, Seibel N, Jaffe E
Pediatr Dev Pathol
. 2005 Feb;
8(1):52-60.
PMID: 15719203
We present the clinicopathologic findings in 4 children with primary cutaneous anaplastic large cell lymphoma (C-ALCL). The patients ranged in age from 13 months to 8 years, with 3 females...
5.
Guerrera M, Ladisch S
Cancer Lett
. 2003 Oct;
201(1):31-40.
PMID: 14580684
Aberrant ganglioside metabolism is linked to tumor progression. Since ganglioside depletion reduced tumorigenicity of MEB4 murine melanoma cells, we studied N-butyldeoxynojirimycin (NB-DNJ), an imino sugar administered orally to inhibit glucosylceramide...
6.
Deng W, Li R, Guerrera M, Liu Y, Ladisch S
Glycobiology
. 2002 Apr;
12(3):145-52.
PMID: 11971858
MEB4 murine melanoma cells synthesize G(M3) as the major ganglioside. Inhibition of G(M3) synthesis by a specific glucosylceramide synthase inhibitor resulted in reduced tumorigenicity and metastatic potential of these cells....